SmallCapReview.com a leading site for news and information on small caps, penny stocks and microcaps is adding MIPS Technologies (Nasdaq: MIPS), SuperGen (Nasdaq: SUPG) and PharmAthene (AMEX: PIP) to its list of stocks "On the Radar".
MIPS Technologies (MIPS) is a leading provider of industry-standard processor architectures and cores that power some of the world's most popular products for the home entertainment, communications, networking and portable multimedia markets. There are millions of MIPS-Based products around the world, these include broadband devices from Linksys, DTVs and digital consumer devices from Sony, DVD recordable devices from Pioneer, digital set-top boxes from Motorola, network routers from Cisco, 32-bit microcontrollers from Microchip Technology and laser printers from Hewlett-Packard.
MIPS Investor Highlights
First Quarter Revenue was $22.5 million, a year-to-year increase of 50 percent.
Licensee royalty units grew to 157 million units from 106 million units in Q1'10.
GAAP net income was $7.6 million or $0.16 per share; up $7.0 million year-to-year.
Cash and investment balances ended the quarter at $65.2 million, a year-to-year increase of $21.7 million.
Debt free.
Announced that 4G chipmaker Sequans Communications has selected its MIPS32(R) M14Kc(TM) synthesizable processor core for next-generation mobile solutions. Sequans is based in Paris, France with additional offices throughout the world, including USA, United Kingdom, Israel, Japan, Hong Kong, Singapore, Taiwan, and China.
Announced that the latest Ethernet switch families from Vitesse Semiconductor Corporation, a leading provider of advanced IC solutions for Carrier and Enterprise networks, are powered by MIPS.
SuperGen (SUPG) is a pharmaceutical company, primarily engaged in the discovery and development of therapies to treat patients with cancer.
The company' products in research and development include Amuvatinib, a multi-targeted Tyrosine Kinase Inhibitor that is specific for mutant forms of c-kit, PDGFRa, and FLT3; SGI-1776Pim Kinase Inhibitor, a novel, orally administered, small molecule anticancer compound that blocks the pro-survival activity of Pim kinases, allowing these potentially malignant cells to self-abort; and SGI-110DNMT1 inhibitor that is in pre-clinical development stage. Its discovery programs comprise JAK2 inhibitor, Axl inhibitor, and ETK/BMX inhibitors; and products that are sublicensed or sold include Dacogen.
SUPG Investor Highlights
The third quarter was another profitable one for SuperGen. Royalties from Dacogen sales increased significantly, and SUPG ended the quarter with more than $112 million in unrestricted cash, cash equivalents and current and non-current marketable securities, and no debt.
The Company raised both royalty revenue and net income guidance for 2010.
Announced SGI-110, a novel, second-generation DNA methylation inhibitor, is on schedule to enter a first-in-human clinical trial in myelodysplastic syndromes and AML during November.
Total revenues for the 2010 third quarter were $13.4 million compared with $10.4 million for the same prior year period.
Net income for the 2010 third quarter of $3.9 million, or $0.06 per basic and diluted share, compared with net income of $833,000, or $0.01 per basic and diluted share, for the same prior year period.
Reported net income for the nine months ended September 30, 2010 of $9.5 million, or $0.16 per basic and diluted share, compared with net income of $2.4 million, or $0.04 per basic and diluted share, for the same prior year period.
PharmAthene (PIP) a biodefense company, together with its subsidiaries, engages in the development and commercialization of medical countermeasures against biological and chemical weapons in the United States.
By following a de-risked strategy of acquiring leading compounds and technologies focused only on high priority medical countermeasures solutions identified by the United States and other governments as urgent to procure, PharmAthene has built a solid product pipeline and a strong reputation within the industry. More than $550 million in United States government contract and funding commitments have been awarded to support the Company’s current product development programs.
PIP Investor Highlights
SIGA was awarded a potential $2.8 billion government contract from the U.S. to produce the smallpox antiviral ST-246. SIGA and PIP were at one point, planning on merging. As part of the merger agreement, it was determined that if the merger did not go through that PIP would be able to exclusively license development and marketing rights for ST-246. The merger did not go through, but PIP never got the license agreement. Hence, PIP is currently suing SIGA, with most analysts agreeing that PIP will win a substantial award.
The company is positioning its anthrax vaccine, Valortim, as a potential alternative to the existing vaccine that is administered to military personnel and individuals who work in high-risk environments. The current vaccine being used produces redness and swelling at the injection site in about 20 percent of patients.
SparVax is a novel second generation recombinant protective (rPA) anthrax vaccine being developed to protect against inhalation anthrax, the most lethal form of anthrax infection in humans. Government funding commitments of up to $213 million have been awarded to date for the SparVax.
Valortim is a fully human monoclonal antibody being developed to protect against inhalation anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody targets PA, a protein component of the toxins produced by the bacterium. Government funding commitments exceeding $27 million have been awarded to-date for the advanced development of Valortim.
Protexia is being developed as a pre- and post-exposure therapy for casualties on the battlefield or civilian victims of nerve agent attacks. PharmAthene was awarded a multi-year contract valued at up to $219 million from the Department of Defense (DoD) U.S. Army Space and Missile Command, for advanced development of Protexia. Additional contract modifications implemented since 2006 have increased the total potential value of the contract up to $223.5 million.
To learn more about these stocks visit http://www.smallcapreview.com
Features available at SmallCapReview.com include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.
No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. SmallCapReview.com has not been compensated by any of the above mentioned companies.
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit http://www.smallcapreview.com.
